In a report released today, David Turkaly from JMP Securities reiterated a Hold rating on Apyx Medical (APYX – Research Report). The company’s shares closed today at $2.33.
According to TipRanks, Turkaly is an analyst with an average return of -4.9% and a 38.00% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as Haemonetics, Orthofix, and Lantheus.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Apyx Medical with a $3.89 average price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $7.97 and a one-year low of $1.41. Currently, Apyx Medical has an average volume of 158.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Apyx Medical (APYX) Company Description:
Apyx Medical Corp. operates as an energy-based medical technology company. It engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME). The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.
Read More on APYX:
